Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2a Study of Systemic PK and Serial ECG Determinations Following 8 Weeks of HyBryte Treatment

Next Previous
Search
Trial Profile

Phase 2a Study of Systemic PK and Serial ECG Determinations Following 8 Weeks of HyBryte Treatment

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hypericin sodium (Primary)
  • Indications Cutaneous T-cell lymphoma; Mycosis fungoides
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Soligenix

    • Most Recent Events

    • 06 Mar 2025 According to a Soligenix media release, company is going to present data which include findings from this study at the United States Cutaneous Lymphoma Consortium (USCLC) Workshop (March 6, 2025).
    • 07 Oct 2024 According to Soligenix media release, the company will give an oral presentation on recent results from this expanded treatment study at the European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Tumour Group Annual Meeting in Lausanne, Switzerland on October 9-11, 2024.
    • 24 Aug 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top